BR112012020976A2 - triazolonas como inibidores de ácido graxo sintase - Google Patents
triazolonas como inibidores de ácido graxo sintaseInfo
- Publication number
- BR112012020976A2 BR112012020976A2 BR112012020976A BR112012020976A BR112012020976A2 BR 112012020976 A2 BR112012020976 A2 BR 112012020976A2 BR 112012020976 A BR112012020976 A BR 112012020976A BR 112012020976 A BR112012020976 A BR 112012020976A BR 112012020976 A2 BR112012020976 A2 BR 112012020976A2
- Authority
- BR
- Brazil
- Prior art keywords
- fatty acid
- acid synthase
- triazolones
- synthase inhibitors
- relates
- Prior art date
Links
- 102000015303 Fatty Acid Synthases Human genes 0.000 title abstract 2
- 108010039731 Fatty Acid Synthases Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- FFSJPOPLSWBGQY-UHFFFAOYSA-N triazol-4-one Chemical class O=C1C=NN=N1 FFSJPOPLSWBGQY-UHFFFAOYSA-N 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30670910P | 2010-02-22 | 2010-02-22 | |
| US35758710P | 2010-06-23 | 2010-06-23 | |
| PCT/US2011/025661 WO2011103546A1 (en) | 2010-02-22 | 2011-02-22 | Triazolones as fatty acid synthase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012020976A2 true BR112012020976A2 (pt) | 2017-05-09 |
Family
ID=44483349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012020976A BR112012020976A2 (pt) | 2010-02-22 | 2011-02-22 | triazolonas como inibidores de ácido graxo sintase |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8802864B2 (https=) |
| EP (1) | EP2538787B1 (https=) |
| JP (1) | JP5805672B2 (https=) |
| KR (1) | KR20120133386A (https=) |
| CN (1) | CN102858175A (https=) |
| AU (1) | AU2011217809A1 (https=) |
| BR (1) | BR112012020976A2 (https=) |
| CA (1) | CA2790692A1 (https=) |
| EA (1) | EA201290822A1 (https=) |
| ES (1) | ES2509951T3 (https=) |
| MX (1) | MX2012009720A (https=) |
| SG (1) | SG183260A1 (https=) |
| WO (1) | WO2011103546A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2509951T3 (es) * | 2010-02-22 | 2014-10-20 | Glaxosmithkline Llc | Triazolonas como inhibidores de sintasa de ácidos grasos |
| WO2013134562A1 (en) * | 2012-03-09 | 2013-09-12 | Inception 2, Inc. | Triazolone compounds and uses thereof |
| AU2013363398B2 (en) | 2012-12-20 | 2017-06-01 | Tempest Therapeutics, Inc. | Triazolone compounds and uses thereof |
| ES2651331T3 (es) * | 2013-01-10 | 2018-01-25 | Glaxosmithkline Intellectual Property (No. 2) Limited | Inhibidores de la sintasa de ácidos grasos |
| SG10201707409PA (en) | 2013-03-13 | 2017-10-30 | Forma Therapeutics Inc | Novel compounds and compositions for inhibition of fasn |
| BR102014021960A2 (pt) | 2013-09-05 | 2015-09-15 | Univ Michigan State | métodos para a produção de arenos borilados |
| US9776976B2 (en) | 2013-09-06 | 2017-10-03 | Inception 2, Inc. | Triazolone compounds and uses thereof |
| WO2015095011A1 (en) * | 2013-12-17 | 2015-06-25 | Janssen Pharmaceutica Nv | Imidazolin-5-one derivative useful as fasn inhibitors for the treatment of cancer |
| TW201625354A (zh) | 2014-06-16 | 2016-07-16 | 陶氏農業科學公司 | 用於製備氧硼基化芳烴之方法 |
| CN104876917B (zh) * | 2015-06-16 | 2017-09-19 | 上海皓元医药股份有限公司 | 用作脂肪酸合成酶抑制剂的三唑酮的合成方法 |
| ES2849951T3 (es) | 2015-06-18 | 2021-08-24 | 89Bio Ltd | Derivados de piperidina 4-bencil y 4-benzoil sustituidos |
| EA201890086A1 (ru) | 2015-06-18 | 2018-06-29 | Сефалон, Инк. | 1,4-замещенные производные пиперидина |
| TW201722957A (zh) * | 2015-09-15 | 2017-07-01 | 葛蘭素史克智慧財產（第二）有限公司 | 化學化合物 |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| US10793554B2 (en) | 2018-10-29 | 2020-10-06 | Forma Therapeutics, Inc. | Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone |
| CN114539193B (zh) * | 2022-01-20 | 2024-08-06 | 安徽普利药业有限公司 | 一种盐酸胺碘酮中间体的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5728834A (en) * | 1996-11-14 | 1998-03-17 | Wyckoff Chemical Company, Inc. | Process for preparation of 4-aryl-1,2,4-triazol-3-ones |
| CA2511970C (en) | 2003-01-14 | 2012-06-26 | Cytokinetics, Inc. | Urea derivatives useful in the treatment of heart failure |
| SE0400850D0 (sv) * | 2004-03-30 | 2004-03-31 | Astrazeneca Ab | Novel Compounds |
| ME01309B (me) * | 2004-08-26 | 2013-12-20 | Pfizer | Pirazolom supstituirani heteroarilni spojevi kao inhibitori proteinskih kinaza |
| CA2627839C (en) * | 2005-11-02 | 2014-08-19 | Bayer Healthcare Ag | Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases |
| US8236792B2 (en) * | 2008-05-23 | 2012-08-07 | Janssen Pharmaceutica Nv | Substituted pyrrolidine amides as modulators of the histamine H3 receptor |
| ES2509951T3 (es) * | 2010-02-22 | 2014-10-20 | Glaxosmithkline Llc | Triazolonas como inhibidores de sintasa de ácidos grasos |
-
2011
- 2011-02-22 ES ES11745417.3T patent/ES2509951T3/es active Active
- 2011-02-22 WO PCT/US2011/025661 patent/WO2011103546A1/en not_active Ceased
- 2011-02-22 AU AU2011217809A patent/AU2011217809A1/en not_active Abandoned
- 2011-02-22 KR KR1020127024682A patent/KR20120133386A/ko not_active Withdrawn
- 2011-02-22 CN CN2011800201452A patent/CN102858175A/zh active Pending
- 2011-02-22 EP EP11745417.3A patent/EP2538787B1/en active Active
- 2011-02-22 MX MX2012009720A patent/MX2012009720A/es unknown
- 2011-02-22 BR BR112012020976A patent/BR112012020976A2/pt not_active Application Discontinuation
- 2011-02-22 US US13/579,040 patent/US8802864B2/en not_active Expired - Fee Related
- 2011-02-22 EA EA201290822A patent/EA201290822A1/ru unknown
- 2011-02-22 SG SG2012059291A patent/SG183260A1/en unknown
- 2011-02-22 JP JP2012554085A patent/JP5805672B2/ja not_active Expired - Fee Related
- 2011-02-22 CA CA2790692A patent/CA2790692A1/en not_active Abandoned
-
2013
- 2013-11-04 US US14/071,093 patent/US9340529B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013520443A (ja) | 2013-06-06 |
| KR20120133386A (ko) | 2012-12-10 |
| US20140100213A1 (en) | 2014-04-10 |
| CA2790692A1 (en) | 2011-08-25 |
| MX2012009720A (es) | 2012-10-09 |
| SG183260A1 (en) | 2012-09-27 |
| US8802864B2 (en) | 2014-08-12 |
| EP2538787A1 (en) | 2013-01-02 |
| AU2011217809A1 (en) | 2012-09-06 |
| US20120316151A1 (en) | 2012-12-13 |
| EA201290822A1 (ru) | 2013-03-29 |
| WO2011103546A1 (en) | 2011-08-25 |
| EP2538787B1 (en) | 2014-07-16 |
| ES2509951T3 (es) | 2014-10-20 |
| CN102858175A (zh) | 2013-01-02 |
| JP5805672B2 (ja) | 2015-11-04 |
| US9340529B2 (en) | 2016-05-17 |
| EP2538787A4 (en) | 2013-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012020976A2 (pt) | triazolonas como inibidores de ácido graxo sintase | |
| WO2012096928A3 (en) | Pyrimidinone derivatives as fatty acid synthase inhibitors | |
| CU24109B1 (es) | Compuestos pirimidinílicos como inhibidores de la cinasa atr | |
| WO2012037299A3 (en) | Fatty acid synthase inhibitors | |
| CL2012003385A1 (es) | Tratamiento para la incontinencia. | |
| CL2014001299A1 (es) | Uso de un conjugado de anticuerpo-fármaco anti-egfrviii (factor de crecimiento epidermico) para tratar tumor. | |
| CL2015000808A1 (es) | Formulaciones liquidas mejoradas de inhibidores de ureasa para fertilizantes. | |
| BR112014017799A8 (pt) | Compostos inibidores de metaloenzima | |
| BR112013010099A2 (pt) | boronatos como inibidores de arginase | |
| IL223201A (en) | Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer | |
| HUE061909T2 (hu) | Pirazolo[1,5-a]pirimidinek alkalmazása ATR kináz inhibítorként, rákos megbetegedések kezelésére | |
| BR112013024502A2 (pt) | ciclopropilaminas como inibidores lsd1 | |
| CO6930363A2 (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
| CR20150217A (es) | Inhibidores de histona demetilasas | |
| DOP2012000238A (es) | Compuestos de para la inhibición de inmunoproteasomas | |
| EA201171367A1 (ru) | Винилиндазолильные соединения | |
| JO3450B1 (ar) | أشكال جرعات تحرير جديدة معدلة لمثبطات زانثين اوكسيدوريدوكتيز أو مثبطات زانثين اوكسيديز | |
| CR20110467A (es) | Derivados de benzofuranilo como inhibidores de la glucoquinasa | |
| AP3849A (en) | Use of inhibitors of the activity or function of pi3k | |
| GT201500094A (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
| BRPI1011912A2 (pt) | l-serina para uso como medicamento para prevenir e/ou tratar uma reação inflamatória da pele. | |
| BR112012024422A2 (pt) | uso de novos inibidores pan-cdk para tratamento de tumores | |
| BR112013016135A2 (pt) | preparação hemostática contendo um extrato de cibotium barometz. | |
| EA201270728A1 (ru) | Пуриновые соединения | |
| AU2016204389A1 (en) | Kinase inhibitors for the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |